newsfilter
← Latest News
GlobeNewswire·

Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™ Phase 3 open-label, safety trial of STS101

ASCEND results expected to support STS101 NDA filing in Q4 2021 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage...